-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BP-1.7881 in Eosinophilic Esophagitis
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.BP-1.7881 in Eosinophilic EsophagitisDrug Details:BPI-7881A is under development for the treatment of atopic dermatitis and eosinophilic...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BP-1.4979 in Binge Eating Disorder
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. BP-1.4979 in Binge Eating Disorder Drug Details: BP-1.4979 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BP-1.4979 in Restless Legs Syndrome
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. BP-1.4979 in Restless Legs Syndrome Drug Details: BP-1.4979 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BP-1002 in Mantle Cell Lymphoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. BP-1002 in Mantle Cell Lymphoma Drug Details: BP-1002 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BP-1.7881 in Atopic Dermatitis (Atopic Eczema)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.BP-1.7881 in Atopic Dermatitis (Atopic Eczema)Drug Details:BPI-7881A is under development for the treatment of atopic dermatitis...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BP-102 in Recurrent Glioblastoma Multiforme (GBM)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. BP-102 in Recurrent Glioblastoma Multiforme (GBM) Drug Details: BP-102 is under investigation for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BP-1002 in Cutaneous T-Cell Lymphoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. BP-1002 in Cutaneous T-Cell Lymphoma Drug Details: BP-1002 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BP-1002 in Relapsed Acute Myeloid Leukemia
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. BP-1002 in Relapsed Acute Myeloid Leukemia Drug Details: BP-1002 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BP-1002 in Refractory Acute Myeloid Leukemia
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. BP-1002 in Refractory Acute Myeloid Leukemia Drug Details: BP-1002 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BP-1002 in Peripheral T-Cell Lymphomas (PTCL)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. BP-1002 in Peripheral T-Cell Lymphomas (PTCL) Drug Details: BP-1002 is under development for the treatment...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.